Recombinant Human CAP3 Protein，His

CAP3, or Cathelicidin Antimicrobial Peptide 3, is a key player in the innate immune response, particularly known for its role in host defense against various pathogens. The research surrounding CAP3 is driven by the increasing prevalence of antibiotic-resistant bacteria and the urgent need for novel antimicrobial agents. CAP3 is part of the cathelicidin family of peptides, which are produced by a wide range of organisms as a first line of defense. Studies have shown that CAP3 exhibits potent antibacterial, antiviral, and antifungal activities, making it a promising candidate for therapeutic applications. Its unique mechanism of action, which disrupts microbial membranes and inhibits microbial growth, sets it apart from traditional antibiotics. Moreover, CAP3 has been implicated in modulation of inflammation and wound healing, further enhancing its potential as a multifunctional therapeutic agent. Investigating the structure-function relationship of CAP3 and optimizing its stability and efficacy through recombinant protein technology has become a focal point for researchers. Understanding the biological pathways influenced by CAP3 can provide insights into developing new strategies for infection control and the treatment of inflammatory diseases. This research not only aims to uncover the mechanistic roles of CAP3 in immunity but also seeks to advance the field of peptide therapeutics, ultimately contributing to the fight against resistant pathogens and improving clinical outcomes for patients with infectious diseases.